Regenerating Heart Using a Novel Compound and Human Wharton Jelly Mesenchymal Stem Cells

Rabbani, Shahram; Soleimani, Masoud; Imani, Mohammad; Sahebjam, Mohammad; Ghiaseddin, Ali; Nassiri, Seyed Mahdi; Ardakani, Jalil Majd; Rostami, Maryam Tajik; Jalali, Arash; Mousanassab, Bahmanshir; Kheradmandi, Mahsa; Tafti, Seyed Hossein Ahmadi

doi:10.1016/j.arcmed.2017.03.019

Cited by 26 publications

(19 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…hMSCs were induced to differentiate to chondrogenic, osteogenic, and adipogenic phenotypes [33]. Recent studies have shown the potential of WJ-MSCs to differentiate towards cardiomyocytes using CHI/HA scaffolds [34]. In our study, we have demonstrated that WJ-MSCs are able to differentiate into endothelial cells on CHI/HA films.…”

Section: Evaluation Of Endothelial Markers Expression At the Mrna Andsupporting

confidence: 57%

Endothelial differentiation of Wharton’s Jelly-derived mesenchymal stem cells seeded on chitosan/hyaluronan multilayer films

Dennaoui¹,

Chouery²,

Harmoush³

2020

CTT

View full text Add to dashboard Cite

The ease of harvesting of mesenchymal stem cells from Wharton's jelly (WJ-MSCs), their great differentiation plasticity and low immunogenicity make them a suitable tool for allogeneic cell therapy. The aim of present study was to explore the potential of WJ-MSCs seeded on chitosan/hyaluronic acid (HA/CHI) multilayers to differentiate into endothelial-like cells. Methods In this study, we differentiate WJ-MSCs into an angiogenic lineage using polyelectrolyte multilayer film as a substrate. WJ-MSCs were cultivated on HA/CHI multilayer film and stimulated (or not) with EGM-2® culture medium. Type I collagen was used as control. mRNA and protein expression of CD31, vascular endothelial growth factor-receptor 2 (VEGF2) and vascular endothelial (VE)-cadherin, along with Dil-acetylated low-density lipoprotein-uptake and von Willebrand Factor protein expression were performed. Results The isolated MSCs showed typical fibroblast-like morphology. We have shown that WJ-MSCs express endothelial markers after 15 days of culture in EGM-2® medium. The mRNA levels were higher on CHI/HA than on collagen for CD31 and KDR, with only KDR increase being statistically significant. At the protein level, a trend for increase in KDR and CDH5 levels was also shown on CHI/HA relative to collagen. Moreover, the WJ-MSCs seeded on CHI/HA showed a high fluorescence specific to von Willebrand factor after endothelial differentiation for 15 days. Conclusion We report here a new biocompatible coating allowing differentiation of WJ-MSCs into endothelial-like cells. This substrate opens new routes in tissue engineering to design allogeneic vascular grafts

show abstract

Section: Evaluation Of Endothelial Markers Expression At the Mrna Andsupporting

confidence: 57%

Endothelial differentiation of Wharton’s Jelly-derived mesenchymal stem cells seeded on chitosan/hyaluronan multilayer films

Dennaoui¹,

Chouery²,

Harmoush³

2020

CTT

View full text Add to dashboard Cite

show abstract

“…Natural materials include collagen ( Chang et al, 2011 ), gelatin ( Chang et al, 2020 ), fibrin ( Rabbani et al, 2017 ), silk fibroin ( Qing et al, 2018 ), alginate ( Yang et al, 2018 ), gellan gum, hyaluronic acid (HA) ( Yazdani et al, 2019 ), chitosan ( Kim et al, 2016 ), Matrigel ( Wang et al, 2020b ); while synthetic polymer materials include poly caprolactone (PCL) ( Zhang et al, 2017 ), polydimethylsiloxane (PDMS) ( McKee et al, 2017 ), polyethylene oxide (PEO) ( Evrova et al, 2016 ), polylactic acid (PLA) ( Gandolfi et al, 2020 ), poly lactic acid-glycolic acid (PLGA) ( Swanson et al, 2020 ), polyvinyl alcohol (PVA) ( Kalachaveedu et al, 2020 ), polyethylene glycol (PEG), tribasic calcium phosphate (TCP) ( Ying et al, 2020 ). Biomaterials used for 3D bioprinting are called “bio-inks.”…”

Section: Methodsmentioning

confidence: 99%

“… Rabbani et al (2017) reported that the combination of Wharton jelly-derived MSCs with a novel compound containing PEG, HA, and chitosan for heart regeneration. The cell/scaffold complex improved defect size and cardiac function, while promoting neoangiogenesis and cardiomyogenesis.…”

Section: Stem Cells (Scs)mentioning

confidence: 99%

Technological Advances of 3D Scaffold-Based Stem Cell/Exosome Therapy in Tissues and Organs

Feng

Waqas

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Most studies comparing the in vivo effect of cells administered in saline with cells administered in hydrogels report an improved beneficial effect in the hydrogel group (Table 2). Furthermore, the majority of recent studies report cell therapy to have a positive effect on LVEF and a larger effect size when administering cells in hydrogel compared to the non-treated group [10,12,15,17,[51][52][53][54][55][56][57]. Other studies found no benefit of cell therapy alone, but only a functional effect of cells in hydrogels [10,[13][14][15][16]48,[58][59][60][61][62].…”

Section: Preclinical Studiesmentioning

confidence: 99%

“…Despite the impressive track record of several synthetic hydrogels, they offer a number of disadvantages from a translational point of view [48,[53][54][55][56]70]. These include possible complicated synthesis processes that are difficult to scale up, high cost, and toxicity inside the human body.…”

Section: Potential Roadblocks For Clinical Translationmentioning

confidence: 99%

Injectable Hydrogels for Improving Cardiac Cell Therapy—In Vivo Evidence and Translational Challenges

Hoeeg

Dolatshahi-Pirouz

Follin

2021

Gels

View full text Add to dashboard Cite

Cell therapy has the potential to regenerate cardiac tissue and treat a variety of cardiac diseases which are currently without effective treatment. This novel approach to treatment has demonstrated clinical efficiency, despite low retention of the cell products in the heart. It has been shown that improving retention often leads to improved functional outcome. A feasible method of improving cell graft retention is administration of injectable hydrogels. Over the last decade, a variety of injectable hydrogels have been investigated preclinically for their potential to improve the effects of cardiac cell therapy. These hydrogels are created with different polymers, properties, and additional functional motifs and differ in their approaches for encapsulating different cell types. Only one combinational therapy has been tested in a clinical randomized controlled trial. In this review, the latest research on the potential of injectable hydrogels for delivery of cell therapy is discussed, together with potential roadblocks for clinical translation and recommendations for future explorations to facilitate future translation.

show abstract

Regenerating Heart Using a Novel Compound and Human Wharton Jelly Mesenchymal Stem Cells

Cited by 26 publications

References 44 publications

Endothelial differentiation of Wharton’s Jelly-derived mesenchymal stem cells seeded on chitosan/hyaluronan multilayer films

Endothelial differentiation of Wharton’s Jelly-derived mesenchymal stem cells seeded on chitosan/hyaluronan multilayer films

Technological Advances of 3D Scaffold-Based Stem Cell/Exosome Therapy in Tissues and Organs

Injectable Hydrogels for Improving Cardiac Cell Therapy—In Vivo Evidence and Translational Challenges

Contact Info

Product

Resources

About